Corcept Therapeutics beat estimated earnings by 66.67%, reporting an EPS of $0.35 versus an estimate of $0.21.
Revenue was up $13.09 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.1, which was followed by a 10.14% increase in the share price the next day.
Here's a look at Corcept Therapeutics's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | 0.2 | 0.16 | 0.21 | 0.19 |
| EPS Actual | 0.3 | 0.30 | 0.20 | 0.27 |
| Revenue Estimate | 97.19M | 86.84M | 91.81M | 87.77M |
| Revenue Actual | 96.13M | 91.59M | 79.44M | 85.73M |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.